zacks.com · 7 jul

FTRE or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

investors.com · 6 jul

This Profitable Autoimmune Biotech Trades Near A High And A Buy Point

This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.

247wallst.com · 1 jul

Live Nasdaq Composite: Markets Kick Off H2 2026 on Cautious Note amid Chip Stock Profit Taking

Live Updates Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now. Wells Fargo's Q3 Outlook 51 minutes ago Live Wells Fargo is betting on a strong summer for stocks, telling clients the Q3 sets up nicely for a rally before midterm election... Live Nasdaq Composite: Markets Kick Off H2 2026 on Cautious Note amid Chip Stock Profit Taking

benzinga.com · 25 jun

Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study

Argenx SE (NASDAQ:ARGX) stock has faced pressure after the company disclosed changes to the analysis plan for its ongoing Phase 3 Vyvgart study in myositis.

investors.com · 24 jun

Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?

Argenx stock reversed course Wednesday, bumping above its 21-day line, as investors digested its myositis-focused R&D Day.

seekingalpha.com · 24 jun

argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript

argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript

marketbeat.com · 12 jun

argenx Eyes More VYVGART Growth as Pipeline Catalysts Near

Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the second half of the year.

investors.com · 10 jun

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.